CIK 0001139685 · <br>Emerging growth company
20/20 Biolabs, Inc.
Sign in to watch- Ticker
- AIDX
- Exchange
- Nasdaq
- Industry
- Services-Testing Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 522272107
- Phone
- 2404536339
- Business address
- 9430 KEY WEST AVENUE, SUITE 100, ROCKVILLE, MD, 20850
- Former names
- 20/20 GeneSystems, Inc., 20/20 GENE SYSTEMS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-02 | Bergman Alan B. Chief Financial Officer | Grant or award · Stock Option | +100,000 | 100,000 | ||
| 2026-04-02 | Zhou Jiming Chief Operating Officer | Grant or award · Stock Option | +150,000 | 150,000 | ||
| 2026-03-03 | Cohen Jonathan M Chief Executive Officer | Grant or award · Stock Option | +352,936 | 352,936 | ||
| 2026-02-19 | Rollins John Woodson Director | Conversion | +13,029 | 24,140 | ||
| 2026-02-19 | Rollins John Woodson Director | Conversion | +6,135 | 30,275 | ||
| 2026-02-19 | Rollins John Woodson Director | Conversion · Series A Preferred Stock | −13,029 | 0 | ||
| 2026-02-19 | Rollins John Woodson Director | Conversion · Series A-2 Preferred Stock | −6,135 | 0 | ||
| 2026-02-19 | Ross Michael A. Director | Conversion | +31 | 31 | ||
| 2026-02-19 | Ross Michael A. Director | Conversion · Series A-2 Preferred Stock | −31 | 0 | ||
| 2026-02-19 | Compton John G. Director | Conversion | +7,669 | 14,335 | ||
| 2026-02-19 | Compton John G. Director | Conversion · Series A-2 Preferred Stock | −7,669 | 0 | ||
| 2026-02-19 | COHEN RICHARD M Director | Conversion | +7,700 | 7,700 | ||
| 2026-02-19 | COHEN RICHARD M Director | Conversion · Series A-2 Preferred Stock | −7,700 | 0 |
Page 1 of 1 · 13 trades